Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 3, Pages 278
Publisher
MDPI AG
Online
2019-02-27
DOI
10.3390/cancers11030278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection
- (2018) Georgios Gemenetzis et al. ANNALS OF SURGERY
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
- (2018) Thierry Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- (2018) Janet E. Murphy et al. JAMA Oncology
- Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
- (2017) Ali A. Mokdad et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
- (2017) Claudio Bassi et al. SURGERY
- Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
- (2017) Changhoon Yoo et al. Oncotarget
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014
- (2017) Kyu-Won Jung et al. Cancer Research and Treatment
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- Approach to Patients With Pancreatic Cancer Without Detectable Metastases
- (2015) Gregory M. Heestand et al. JOURNAL OF CLINICAL ONCOLOGY
- Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
- (2015) Moh'd Khushman et al. PANCREATOLOGY
- A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
- (2013) Eileen M. OʼReilly et al. ANNALS OF SURGERY
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
- (2013) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
- (2012) Jae-Lyun Lee et al. SURGERY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started